CLINICAL REPORT

A novel CLCNKB variant in a Chinese family with classic Bartter syndrome and prenatal genetic diagnosis

Qianying Zhao1,2 | Qinqin Xiang1,2 | Yu Tan1,2 | Xiao Xiao1,2 | Hanbing Xie1,2 | He Wang1,2 | Mei Yang1,2 | Shanling Liu1,2

1Department of Obstetrics & Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China
2Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, China

Correspondence
Mei Yang and Shanling Liu, Department of Obstetrics & Gynecology, West China Second University Hospital, No. 20, Section 3, Renminnan Road, Chengdu, Sichuan, 610041, China.
Email: yangmei03182016@163.com (M. Y.); sunny630@126.com (S. L.)

Funding information
National Key Research and Development Program of China, Grant/Award Number: 2021YFC1005303; Science and Technology Department of Sichuan Province, Grant/Award Number: 2021YFS0078

Abstract

Background: Type III Bartter syndrome (BS), often known as classic Bartter syndrome, is caused by variants in CLCNKB gene, which encoding the basolateral chloride channel protein ClC-Kb, and is characterized by renal salt wasting, hypokalemia, metabolic alkalosis, increased renin, and aldosterone levels.

Methods: A 2-year-old boy presented severe malnutrition, severe metabolic alkalosis and severe hypokalemia and was clinically diagnosed with BS. The trio exome sequencing (ES) was performed to discover the genetic cause of this patient, followed by validation using Sanger sequencing and quantitative polymerase chain reaction subsequently.

Results: The genetic analysis indicated that this patient with a compound heterozygous variants of CLCNKB gene including a novel nonsense variant c.876 T > A and a whole-gene deletion. The two variants were inherited from his parents, respectively. Subsequently, target sequencing of CLCNKB gene was performed for next pregnancy, and prenatal genetic diagnosis was provided for the family.

Conclusions: The results of current study identified the compound heterozygous variants in a patient with classic BS. The novel variant expands the spectrum of CLCNKB variants in BS. Our study also indicates that ES is an alternative tool to simultaneously detect single-nucleotide variants and copy-number variants.

KEYWORDS
classic Bartter syndrome, CLCNKB, exome sequencing, prenatal genetic diagnosis

1 INTRODUCTION

Bartter syndrome (BS) is a rare autosomal recessive salt-losing tubulopathy, characterized by hypokalemic metabolic alkalosis, hyperreninemic hyperaldosteronism with normal-to-low blood pressure, and juxtaglomerular apparatus cell hyperplasia (Bartter et al., 1962; Hebert, 2003).

BS has been clinically classified into two types: antenatal BS (aBS) and classic BS (cBS). Compared with cBS, patients with aBS exhibit severe symptoms, such as
maternal polyhydramnios, premature birth, and growth retardation (Brochard et al., 2009; Laghmani et al., 2016).

Also, BS is categorized into five genetic subtypes (types I-V) based on the underlying variant genes: Type I BS (OMIM: 601678) is caused by variants in SLC12A1 gene (OMIM: 600839), which encodes the sodium–potassium–chloride cotransporter NKCC2; Type II BS (OMIM: 241200) is caused by variants in KCNJ1 gene (OMIM: 600359) which encodes the apical inwardly rectifying potassium channel ROMK; Type III BS (OMIM: 607364) is caused by variants in CLCNKB gene (OMIM: 602023), which encodes the basolateral chloride channel protein ClC-Kb; Type IVa BS (OMIM: 602522) is caused by variants in BSND gene (OMIM: 606412), which encodes barttin, an essential beta subunit for the chloride channels CLCNKA and CLCNKB. Type IVb BS is caused by simultaneous variants in both CLCNKB (OMIM: 602023) and CLCNKA (OMIM: 602024) genes. Type V BS (OMIM: 300971) is caused by variants in MAGED2 gene (OMIM: 300470), which encodes melanoma associated antigen D2 (Al Shibli & Narchi, 2015; Hebert, 2003; Laghmani et al., 2016; Seyberth, 2008).

Type III BS is also known as cBS, caused by the pathogenic variants in CLCNKB gene, which mapped in chromosome 1p36.13 and encoding the basolateral chloride channel ClC-Kb. ClC-Kb is a vital member of the ClC chloride channel family, which plays a very important role in the trans-membrane transport of chloride in the renal tubules (Zelikovic et al., 2003). As a result, disease-causing variants could inactivate ClC-Kb, reducing the reabsorption of chloride. Subsequently sodium reabsorption would also be reduced. Due to the loss of water and sodium chloride, the renin–angiotensin–aldosterone system further activates and the loss of potassium aggravates (Andrini et al., 2015; Zelikovic et al., 2003). The phenotype of cBS is highly variable, including sporadical volume depletion and dehydration during early infancy, short stature, and polyuria during childhood or asymptomatic hypokalemia (Jeck et al., 2000; Konrad et al., 2000).

In this study, we reported clinical and molecular findings from a patient with cBS. The patient carried a novel nonsense variant (c.876T>A, p.Cys292*) combined with the entire gene deletion of CLCNKB inherited from his parents, respectively.

2 | MATERIALS AND METHODS

2.1 | Clinical summary

A 2-year-old boy presented a history of growth retardation and abnormal homeostasis. His mother had a history of polyhydramnios at 30+ weeks of gestation, but no interventional prenatal genetic diagnosis (e.g., chromosome microarray analysis) was further performed during pregnancy. The boy was delivered at term, with a birth weight of 3500 g and length of 50 cm. However, he was diagnosed as “malnutrition” at the local hospital at the age of 2+ months, manifesting mainly as milk-spitting and feeding difficulties. At the age around 7 months, he was transferred to pediatric department in West China Second University Hospital of Sichuan University, and blood tests demonstrated electrolyte disorders: Na+ fluctuated between 124–129 mmol/L, K+ fluctuated between 1.5 and 2.6 mmol/L, and Cl− fluctuated between 76–83 mmol/L, with elevated arterial pH (7.59–7.67). Plasma aldosterone was markedly elevated (33.93 ng/dL), with normal results of metabolic-disease screening. No significant anomalies were uncovered through brain and chest CT, as well as echocardiography.

He was clinically diagnosed with BS, severe malnutrition, internal environment disorder: severe metabolic alkalosis, severe hypokalemia, hyponatremia, and hypochloremia. Oral spironolactone, indomethacin, and potassium supplements improved his serum electrolyte level (Table 1), without muscle weakness, polydipsia, and arrhythmia. At the age of 1 year old, he had two episodes of tetany after diarrhea and fever, respectively, with bilateral

| TABLE 1 | Blood gas level |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Concentration age (months) | Sodium (135-145 mmol/L) | Potassium (3.5-5.5 mmol/L) | Calcium (1.09-1.30 mmol/L) | Chloride (96-108 mmol/L) | PH (7.35-7.45) |
| 7 | 124–129 | 1.5–2.6 | 1.01–1.12 | 76–83 | 7.59–7.67 |
| 8 | 125–128 | 2.5–2.9 | 1.25–1.29 | 87–88 | 7.53–7.55 |
| 9 | 133 | 3.4 | 1.22 | 97 | 7.5 |
| 10 | 129 | 2.6–3.0 | 1.10–1.17 | 87–92 | 7.62 |
| 11 | 130 | 2.9 | 1.16 | 92 | 7.49 |
| 12 | 127 | 3.0 | 1.08 | 86 | 7.56 |
| 18 | 131 | 3.8 | 1.20 | 98 | 7.49 |
| 24 | 136 | 3.4 | 2.54 | 95 | N/A |
limb rigidity, staring gaze, circumoral cyanosis, and loss of consciousness. The electroencephalography was normal. Except fullness of the anterior fontanelle and slightly reduced density at local white matter of bilateral frontoparietal lobes, no remarkable abnormalities were detected on craniocerebral CT. Although continuous symptomatic treatment could maintain the stasis of internal environment, the subject was assessed as moderate to severe growth and psycho-motor retardation at local rehabilitation center. At the age of 2 years, his height was 80 cm (<3rd percentile), his weight was 10 kg (3rd percentile). He could merely speak double-syllable words and accomplish simple instructions, denial of communication resistance or stereotyped behaviors. According to the regular follow-up, he had no proteinuria or renal dysfunction.

His mother and father were non-consanguineous, and there was no family history of congenital malformations or genetic diseases. The pedigree of the family is shown in Figure 1. His mother was pregnant again, amniocentesis was performed at 23 weeks of gestation. DNA extracted from the amniocytes was tested by massive parallel sequencing, targeting at genetic variants found by exome sequencing (ES) in the proband.

2.2 | Exome sequencing

Genomic DNA of the family members was extracted from peripheral blood leukocytes using QIAamp DNA Blood Mini Kit (QIAGEN). To reveal the genetic causes for the proband, trio-ES was performed using genomic DNA from the family members (II-1, II-2, III-1).

Exome capture sequencing was performed using the NanoWES Human Exome V1 (Berry genomics) following the manufacturer’s protocol. The DNA libraries after enrichment and purification were sequenced through Illumina NovaSeq6000 platform with 150-bp paired-end reads.

Next, Burrows-Wheeler Aligner software tool was used for aligning the sequencing reads with hg38/GRCh38. After that, local alignment and recalibration of base quality of the Burrows-Wheeler aligned reads was performed by the GATK Indel Realigner and the GATK Base Recalibrator, respectively (broadinstitute.org). Then, single-nucleotide variants (SNVs) and small insertions or deletions (InDels) were identified by GATK Unified Genotyper (broadinstitute.org). Finally, functional annotation was performed using ANNOVAR and the Enliven Variants Annotation Interpretation System (Berry genomics).

Public databases using for filtering consist of gnomAD (http://gnomad.broadinstitute.org/), 1000 Genomes Project (1000G) (http://browser.1000genomes.org), and etc. Pathogenicity of the detected SNVs were evaluated based on the scientific medical literature and disease databases, including OMIM (http://www.omim.org), PubMed (https://www.ncbi.nlm.nih.gov/pubmed), ClinVar (http://www.ncbi.nlm.nih.gov/clinvar), and Human Gene Mutation Database (HGMD) (http://www.hgmd.org). The detailed process for identifying the variants is described previously (Yang, Xie, et al., 2021; Yang, Xu, et al., 2021).

2.3 | Sanger sequencing and quantitative polymerase chain reaction

Sanger sequencing was underwent in validating candidate variants on each independent gDNA sample (II-1, II-2, III-1). Polymerase chain reaction (PCR) amplification was performed using primer pairs (Table 2) designed to cover variants identified by ES.

Triplicate quantitative PCR for gDNA was performed using SYBR Green quantitative polymerase chain reaction (qPCR) Master Mix (Thermo Fisher Scientific, 00850445) on a RT-PCR System (Thermo Fisher Scientific, 7500 Real-Time PCR Systems). Delta CT value analysis method was performed to evaluate relative copy number of genome exon 10 and exon 18. Specific and internal control gene primer pairs were as well designed using Primer 3 software Version 0.4.0 (http://bioinfo.ut.ee/primer3-0.4.0/) (Table 2). Sequencing of PCR products were conducted by ABI 3500 Genetic Analyzer (Thermo Fisher Scientific). Data were evaluated using the Chromas software (2.6.5).

2.4 | Prenatal genetic diagnosis

The mother of the proband was then pregnant later, and opted to undergo prenatal genetic diagnosis of the variants identified in the proband. Amniocentesis was performed at 23 weeks of gestational. ES was performed on the DNA
extracted from amniocytes of CLCNKB gene and variants were validated by Sanger sequencing as well as qPCR.

3 | RESULTS

3.1 | Novel CLCNKB variant in a Chinese family with cBS

To elucidate the underlying genetic etiology of cBS for this family, trio-ES was performed. The results indicated that a novel nonsense variant c.876T>A (p.Cys292*, NM_000085.5) of the CLCNKB gene was identified in the proband and inherited from his father. The presence of this variant was further validated by Sanger sequencing (Figure 2a). This nonsense was detected in the proband and his father but not in his mother. The novel heterozygous variant p.Cys292* in the exon 10 of CLCNKB, resulting in a change in cysteine acid to a premature stop codon at amino acid position 292 (p.Cys292*), has not been reported in any public database, such as HGMD, ClinVar or GnomAD databases. A synonymous variant (c.876 T>C, p.Cys292Cys, NM_000085.5) also was detected in his father and mother. However, the C allele is common in the general population of the same nucleotide sequence, which is also a benign synonymous substitution (BA1, BP7) (https://gnomad-sg.org/region/1-16049824-16049824?dataset=gnomad_r3).

The results of trio-ES indicated that the proband also had a heterozygous deletion of the whole CLCNKB gene and inherited from his mother. This deletion was further confirmed by qPCR analysis on specific exons (Figure 2b). The qPCR analysis results showed that compared with the father, the proband and their mother. All the values are means ± SEM from three independent experiments, and statistical analysis was performed by one-way ANOVA.
copy for exon 10, exon 18, which indicated that the heterozygous deletion was detected in the proband and his mother but not in his father. Together, the proband had both variants including a paternal-inherited nonsense variant c.876T>A in CLCNKB gene and a maternal-inherited entire gene deletion of the same gene. According to the criteria of ACMG, the nonsense variant on was categorized as pathogenic variant (PVS1, PM2, PP4) and the entire gene deletion was categorized as pathogenic variant (PVS1, PM3, PP4).

### 3.2 Prenatal genetic diagnosis

The prenatal genetic diagnosis targeting CLCNKB gene using amniocytes showed that the fetal genotype was compound heterozygous as well, carrying both the nonsense variant c.876T>A and an entire CLCNKB gene deletion. Validation was performed using Sanger sequencing and qPCR subsequently (Figure 2). No abnormal findings were uncovered through routine antenatal care till amniocentesis.

### 4 DISCUSSION

In our study, we identified a compound heterozygous pathogenesis for the CBS proband: a novel nonsense variant c.876T>A and an entire gene deletion. The pathogenic variants in the CLCNKB gene are the molecular basis for CBS (Simon et al., 1997). The clinical manifestation of CLCNKB disorder is a highly variable, overlapping with either aBS or Gitelman syndrome (GS) (Zelikovic et al., 2003). GS is a milder disease frequently associated with hypomagnesemia and hypocalciuria, while hypomagnesemia and hypocalciuria are not always present. GS is caused by dysfunction of SLC12A3 (Ma et al., 2016). Thus, the genetic analysis can more effectively differentiate GS and BS.

According to the HGMD (http://www.hgmd.cf.ac.uk), more than 196 variants have been reported in CLCNKB gene, including 103 missense or nonsense variants, 22 splice site variants, 24 small deletions, 39 gross deletions, 5 small insertions, and 3 complex rearrangements. Previous studies indicated that the entire gene deletion were of the highest allele frequency (Han et al., 2017, 2020). Heterozygous whole-or partial-gene deletions related to recessive inherited disease genes play a vital role in an individual’s recessive carrier status (Boone et al., 2013), and also directly lead to disease by introducing compound heterozygous state where a deletion on one chromosome homolog coexisted with a loss of function or hypomorphic SNV allele on the other homolog elsewhere (Charg et al., 2016; Kremer et al., 2016; Lalan et al., 2016; Stray-Pedersen et al., 2017; Wu et al., 2015). Herein, our ES result revealed that a maternal heterozygous deletion and a paternal nonsense variant in CLCNKB gene in our patient, which has been considered to contribute to BS. WES has been widely used as a first-tier diagnostic tool to identify genetic causes of many suspicious Mendelian disorders. WES could detect different types of variants including SNVs, indels and copy-number variants (CNVs) in the meantime. However, due to the false positive rates of the CNVs identified from WES, data are highly recommended to be validated by an orthogonal methods, such as multiplex ligation-dependent probe amplification, SNP-array, CNV-seq, or qPCR (Ellingford et al., 2017; Kerkhof et al., 2017; Rajagopalan et al., 2020). Thus, qPCR was performed for validation for the family in our study.

Type III BS is characterized by salt reabsorption defect in the thick ascending limb of the Henle loop (Seyberth & Schlingmann, 2011). The main treatment is potassium supplement to reduce potassium loss, correct hypokalemia, and metabolic alkalosis. In addition, the use of prostaglandin synthesis inhibitors, such as NSAIDs, is an alternative therapy (Friis et al., 2005; Jensen et al., 1996; Verberckmoes et al., 1976; Wu et al., 2020). Nonetheless, there is no curative therapy for CBS up till now. Previous study reported that certain BS type III patients exhibited pathological proteinuria and kidney dysfunction even under treatment (Bettinelli et al., 2007). Moreover, the clinical characterization of CBS are highly heterogeneous, including polyuria, polydipsia, dehydration, developmental retardation, renal dysfunction, even sudden death in certain cases. Therefore, the prenatal genetic diagnosis is significantly necessary. In this study, target sequencing of these variants was performed for the fetus when the proband’s mother was pregnant again. Unfortunately, both pathogenic variants identified in the proband were also detected in amniocytes, providing valuable prognosis information for this family. This couple decided to terminate the pregnancy after genetic counseling.

Of note, type IV b BS is caused by simultaneous variants in both the CLCNKB and CLCNKA genes (Nozu et al., 2008; Schlingmann et al., 2004), which contribute to a severe form of BS and sensorineural deafness. Hence, in view of the digenic inheritance of BS, these two genes should be considered to be sequenced simultaneously in the patients with severe BS manifestations. In addition, the type IV b BS and other aBS also result in severe maternal polyhydramnios during the pregnancy, fetal ES, which has been more widely used during pregnancy, could be recommended to identify gene variants related to BS.

To sum up, in the present study, compound heterozygous variants in CLCNKB gene were discovered for a CBS
patient using ES, consisting of a novel nonsense variant (c. 876T>A) and a whole gene deletion, which result in biallelic loss-of-function of this gene. The novel variant expands the spectrum of CLCNKB variants in BS. Subsequently, our outcomes provide important information for subsequent genetic counseling and prenatal genetic diagnosis of this family. Furthermore, the present study indicates that ES is an effective tool to uncover the genetic etiology for Mendelian disorders, which could simultaneously detect different types of variants.

AUTHOR CONTRIBUTIONS
QYZ and MY designed the study experiments. QYZ and XX collected the data and conducted the clinical evaluations. QQX, YT, and HBX performed PCR-seq. QYZ and MY wrote the article. MY, SLL, and HW supervised the study experiments. All authors revised and approved the article.

ACKNOWLEDGMENTS
We sincerely thank the patient and his family for their interest and cooperation.

FUNDING INFORMATION
This study was supported by the National Key Research and Development Program of China (2021YFC1005303) and the Science and Technology Department of Sichuan Province, China (2021YFS0078).

CONFLICT OF INTEREST
The authors declare no conflict of interests.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ETHICAL COMPLIANCE
Experiment on human subjects was approved by the Ethical Review Board of West China Second University Hospital, Sichuan University.

CONSENT TO PARTICIPATE
Informed consent for participation to this study was obtained from the parents of the patients.

PATIENT CONSENT FOR PUBLICATION
Publication of data was informed consent to the parents of the patients involved in this study.

ORCID
Qianying Zhao https://orcid.org/0000-0003-3026-4827
Mei Yang https://orcid.org/0000-0002-6200-5865

REFERENCES
Al Shibli, A., & Narchi, H. (2015). Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations. *World Journal of Methodology, 5*(2), 55–61. https://doi.org/10.5662/wjmm.v5.i2.55
Andrini, O., Keck, M., Briones, R., Lourdel, S., Vargas-Poussou, R., & Teulon, J. (2015). ClC-K chloride channels: Emerging pathophysiology of Bartter syndrome type 3. *American Journal of Physiology. Renal Physiology, 308*(12), F1324–F1334. https://doi.org/10.1152/ajprenal.00004.2015
Bartter, F. C., Pronove, P., Gill, J. R., Jr., & Maccardle, R. C. (1962). Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. *The American Journal of Medicine, 33*, 811–828. https://doi.org/10.1016/0002-9343(62)92014-0
Bettinelli, A., Borsa, N., Bellantuono, R., Syrén, M. L., Calabrese, R., Edelfonti, A., Komminos, J., Santostefano, M., Beccaria, L., Pela, I., Blanchetti, M. G., & Tedeschi, S. (2007). Patients with biallelic mutations in the chloride channel gene CLCNKB: Long-term management and outcome. *American Journal of Kidney Diseases, 49*(1), 91–98. https://doi.org/10.1053/j.ajkd.2006.10.001
Boone, P. M., Campbell, I. M., Baggett, B. C., Soens, Z. T., Rao, M. M., Hixson, P. M., Patel, A., Bi, W., Cheung, S. W., Lalani, S. R., Beaudet, A. L., Stankiewicz, P., Shaw, C. A., & Lupski, J. R. (2013). Deletions of recessive disease genes: CNV contribution to carrier states and disease-causing alleles. *Genome Research, 23*(9), 1383–1394. https://doi.org/10.1101/gr.156075.113
Brochard, K., Boyer, O., Blanchard, A., Loirat, C., Niaudet, P., Macher, M. A., Deschenes, G., Bensman, A., Decramer, S., Cochat, P., Morin, D., Broux, F., Cailliez, M., Guyot, C., Novo, R., Jeunemaitre, X., & Vargas-Poussou, R. (2009). Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome. *Nephrology, Dialysis, Transplantation, 24*(5), 1455–1464. https://doi.org/10.1093/ndt/gfn689
Charg, W. L., Karaca, E., Coban Akdemir, Z., Gambin, T., Atik, M. M., Gu, S., Posey, J. E., Jiangiani, S. N., Muzny, D. M., Doddapaneni, H., Hu, J., Boerwinkle, E., Gibbs, R. A., Rosenfeld, I. A., Cui, H., Xia, F., Manickam, K., Yang, Y., Faqeih, E. A., ... Lupski, J. R. (2016). Exome sequencing in mostly consanguineous Arab families with neurologic disease provides a high potential molecular diagnosis rate. *BMC Medical Genomics, 9*(1), 1–14. https://doi.org/10.1186/s12920-016-0208-3
Ellingford, J. M., Campbell, C., Barton, S., Bhaskar, S., Gupta, S., Taylor, R. L., Sergouniotis, P. I., Horn, B., Lamb, J. A., Michaelides, M., Webster, A. R., Newman, W. G., Panda, B., Ramsden, S. C., & Black, G. C. (2017). Validation of copy number variation analysis for next-generation sequencing diagnostics. *European Journal of Human Genetics, 25*(6), 719–724. https://doi.org/10.1038/ejhg.2017.42
Friis, U. G., Stubbe, J., Uhrenholt, T. R., Svenningsen, P., Nüsing, R. M., Skott, O., & Jensen, B. L. (2005). Prostaglandin E2 EP2 and EP4 receptor activation mediates cAMP-dependent hyperpolarization and exocytosis of renin in juxtaglomerular cells. *American Journal of Physiology. Renal Physiology, 289*(5), F989–F997. https://doi.org/10.1152/ajprenal.00201.2005
Han, Y., Cheng, H., Shao, S., Lang, Y., Zhao, X., Lin, Y., Wang, S., Shi, X., Liu, Z., & Shao, L. (2020). Thirteen novel CLCNKB variants
and genotype/phenotype association study in 42 Chinese patients with Bartter syndrome type 3. Endocrine, 68(1), 192–202. https://doi.org/10.1007/s12020-019-02156-9

Han, Y., Lin, Y., Sun, Q., Wang, S., Gao, Y., & Shao, L. (2017). Mutation spectrum of Chinese patients with Bartter syndrome. Oncotarget, 8(60), 101614–101622. https://doi.org/10.18632/oncotarget.21355

Hebert, S. C. (2003). Bartter syndrome. Current Opinion in Nephropathy and Hypertension, 12(5), 527–532. https://doi.org/10.1097/00041552-200309000-00008

Jeck, N., Konrad, M., Peters, M., Weber, S., Bonzel, K. E., & Seyberth, H. W. (2000). Mutations in the chloride channel gene, CLCNKB, leading to a mixed Bartter-Gitelman phenotype. Pediatric Research, 48(6), 754–758. https://doi.org/10.1203/00006450-200012000-00009

Jensen, B. L., Schmid, C., & Kurtz, A. (1996). Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells. The American Journal of Physiology, 271(3 Pt 2), F659–F669. https://doi.org/10.1152/ajpre.nal.1996.271.3.F659

Kerkhof, J., Schenkel, L. C., Reilly, J., McRobbie, S., Aref-Eshghi, T., Igarashi, T., Nakanishi, K., Yoshikawa, N., Iijima, K., & Matsuo, M. (2008). Molecular analysis of digenic inheritance in Bartter syndrome with sensorineural deafness. Journal of Medical Genetics, 45(3), 182–186. https://doi.org/10.1136/jmg.2007.052944

Rajagopalan, R., Murrell, J. R., Luo, M., & Conlin, L. K. (2020). A highly sensitive and specific workflow for detecting rare copy-number variants from exome sequencing data. Genome Medicine, 12(1), 1–11. https://doi.org/10.1186/s13073-020-0712-0

Schlimgang, K. P., Konrad, M., Jeck, N., Waldegger, P., Reinalter, S. C., Holder, M., Seyberth, H. W., & Waldegger, S. (2004). Salt wasting and deafness resulting from mutations in two chloride channels. The New England Journal of Medicine, 350(13), 1314–1319. https://doi.org/10.1056/NEJMoa032843

Seyberth, H. W. (2008). An improved terminology and classification of Bartter-like syndromes. Nature Clinical Practice. Nephrology, 4(10), 560–567. https://doi.org/10.1038/ncpneph0912

Seyberth, H. W., & Schlimgang, K. P. (2011). Bartter- and Gitelman-like syndromes: Salt-losing tubulopathies with loop or DCT defects. Pediatric Nephrology, 26(10), 1789–1802. https://doi.org/10.1007/s00467-011-1871-4

Simon, D. B., Bindra, R. S., Mansfield, T. A., Nelson-Williams, C., Mendonca, E., Stone, R., Schurman, S., Nayir, A., Alpay, H., Bakkaloglu, A., Rodriguez-Soriano, J., Morales, J. M., Sanjad, S. A., Taylor, C. M., Pilz, D., Brem, A., Trachtman, H., Griswold, W., Richard, G. A., ... Lifton, R. P. (1997). Mutations in the chloride channel gene, CLCNKB, cause Bartter’s syndrome type III. Nature Genetics, 17(2), 171–178. https://doi.org/10.1038/ng1097-171

Stray-Pedersen, A., Sorte, H. S., Samarakoon, P., Gambin, T., Chinn, I. K., Coban Akdemir, Z. H., Erichsen, H. C., Forbes, L. R., Gu, S., Yuan, B., Jiangiani, S. N., Muzny, D. M., Rödningen, O. K., Sheng, Y., Nicholas, S. K., Noroski, L. M., Seeborg, F. O., Davis, C. M., Canter, D. L., ... Lupski, J. R. (2017). Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders. The Journal of Allergy and Clinical Immunology, 139(1), 232–245. https://doi.org/10.1016/j.jaci.2016.05.042

Verberckmoes, R., van Damme, B. B., Clement, J., Amery, A., & Michielsens, P. (1976). Bartter’s syndrome with hyperplasia of renomedullary cells: Successful treatment with indomethacin. Kidney International, 9(3), 302–307. https://doi.org/10.1038/ki.1976.33

Wu, N., Ming, X., Xiao, J., Wu, Z., Chen, X., Shinawi, M., Shen, Y., Xu, G., Liu, J., Xie, H., Gucev, Z. S., Liu, S., Yang, N., Al-Kateb, H., Chen, J., Zhang, J., Hauser, N., Zhang, T., Tasic, V., ... Zhang, F. (2015). TBX6 null variants and a common hypomorphic allele in congenital scoliosis. The New England Journal of Medicine, 372(4), 341–350. https://doi.org/10.1056/NEJMoa1406829

Wu, X., Yang, G., Chen, S., Tang, M., Jian, S., Chen, F., & Wu, X. (2020). Bartter syndrome with long-term follow-up: A case
The report. *The Journal of International Medical Research*, 48(8), 300060520947876. https://doi.org/10.1177/0300060520947876

Yang, M., Xie, H., Xu, B., Xiang, Q., Wang, H., Hu, T., & Liu, S. (2021). Identification of a novel EXT2 frameshift mutation in a family with hereditary multiple exostoses by whole-exome sequencing. *Journal of Clinical Laboratory Analysis*, 35(9), e23968. https://doi.org/10.1002/jcla.23968

Yang, M., Xu, B., Wang, J., Zhang, Z., Xie, H., Wang, H., Hu, T., & Liu, S. (2021). Genetic diagnoses in pediatric patients with epilepsy and comorbid intellectual disability. *Epilepsy Research*, 170, 106552. https://doi.org/10.1016/j.eplepsyres.2021.106552

Zelikovic, I., Szargel, R., Hawash, A., Labay, V., Hatib, I., Cohen, N., & Nakhoul, F. (2003). A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes. *Kidney International*, 63(1), 24–32. https://doi.org/10.1046/j.1523-1755.2003.00730.x

**How to cite this article:** Zhao, Q., Xiang, Q., Tan, Y., Xiao, X., Xie, H., Wang, H., Yang, M., & Liu, S. (2022). A novel CLCNKB variant in a Chinese family with classic Bartter syndrome and prenatal genetic diagnosis. *Molecular Genetics & Genomic Medicine*, 10, e2027. https://doi.org/10.1002/mgg3.2027